Bioconjugates Stream

- 生物共轭 -

Antibody-Drug Conjugates Come of Age

The field of ADCs has experienced its fair share of ups-and-downs on the road to clinic and regulatory approvals. Finally, this year we saw the approval of POLIVY™, with several promising ADCs drumming up the excitement in the coming months. To highlight the dynamic landscape, CHI’s Bioconjugates Stream will present a 2-part Antibody-Drug Conjugates program:

Part 1: Engineering Antibody-Drug Conjugates invites scientists to discuss novel design strategies to engineer the right ADC combinations, using novel payloads, new non-IgG platforms, and/or creative linker/conjugation technologies.

Part 2: Clinical Progress of Antibody-Drug Conjugates invites investigators to share their latest results from preclinical to clinical trials, lessons learned from past ADC programs and related fields to inform next-gen ADC design, and to develop better predictability for translation from bench to clinic.

Conferences Include:

5月6 - 7日

Engineering Antibody-Drug Conjugates
( 抗体药物复合体工程 )

5月7 - 8日

Clinical Progress of Antibody-Drug Conjugates
( 抗体药物复合体的临床开发进展 )

Keynote Speakers:

Rakesh Dixit, DAPT PhD, President & CEO, Bionavigen

Greg Thurber, PhD Associate Professor, Chemical Engineering and Biomedical Engineering, University of Michigan

Choose your language